Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cash-rich Japanese Pharma Now In A Position To Snatch Up Compounds, But Many Face Decision-making Bottlenecks - BIO Japan

This article was originally published in PharmAsia News

Executive Summary

YOKOHAMA, Japan - The impact of the strong yen appreciation has been severe for Japanese companies, contributing to sales dips as foreign markets balked at the rising prices for Japanese products. But the strong yen can also be a positive for Japanese consumers, including Japan Pharma shopping around for early-stage biotech compounds

You may also be interested in...



Daiichi Sankyo Taps Japan Government Capital For New Seed Fund

Daiichi Sankyo and Mitsubishi UFJ – with ¥450 million in government backing – launched a fund to develop university venture technology for Daiichi Sankyo’s pipeline.

Prism Finds Funding From Japanese Government VC To Launch New Trials

Prism’s lead compound is already in-licensed by Eisai for cancer indications, and the startup is now looking for a partner for the compound’s fibrosis indications now that Phase I plans are in the works.

Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Sankyo Buyout

Bidding by multiple companies and strong data for a late-stage, targeted melanoma drug helped drive Daiichi Sankyo Company Limited's eye-popping $805 million acquisition of privately-held Plexxikon Inc.

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel